Question: What American biotechnology company is part of Gloucester Pharmaceuticals?
Sentence (from "Celgene"): Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Relevant evidence: No